Parathyroid hormone 1-84 targets bone vascular structure and perfusion in mice: Impacts of its administration regimen and of ovariectomy

Journal of Bone and Mineral Research

Volumn 29, Issue 7, 2014, Pages 1608-1618

  Roche, Bernard ^a   Vanden Bossche, Arnaud ^a   Malaval, Luc ^a   Normand, Myriam ^a   Jannot, Martin ^a   Chaux, Robin ^a   Vico, Laurence ^a   Lafage Proust, Marie Hélène ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

BONE PERFUSION; BONE REMODELING; BONE VASCULARIZATION; PTH; VASCULAR REMODELING

Indexed keywords

PARATHYROID HORMONE; PROPRANOLOL; RECOMBINANT PARATHYROID HORMONE; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; BONE DENSITY; BONE REMODELING; BONE STRUCTURE; BONE TURNOVER; C57BL 6 MOUSE; CONTROLLED STUDY; DOPPLER DEVICE; DRUG EFFECT; FEMALE; IN VIVO STUDY; MICROVASCULATURE; MORPHOMETRICS; MOUSE; NONHUMAN; OSMOTIC PUMP; OSSIFICATION; OVARIECTOMY; PERFUSION; TIBIA; ANATOMY AND HISTOLOGY; ANIMAL; BONE DEVELOPMENT; C57BL MOUSE; DRUG EFFECTS; HEMODYNAMICS; MICRO-COMPUTED TOMOGRAPHY; RADIOGRAPHY; TIME; VASCULARIZATION;

ANIMALS; DIPHOSPHONATES; FEMALE; HEMODYNAMICS; IMIDAZOLES; MICE, INBRED C57BL; OSTEOGENESIS; OVARIECTOMY; PARATHYROID HORMONE; PERFUSION; PROPRANOLOL; TIBIA; TIME FACTORS; X-RAY MICROTOMOGRAPHY;

EID: 84902982033     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2191     Document Type: Article

References (61)

1. Kristensen HB, Andersen TL, Marcussen N, Rolighed L, Delaisse J-M., Increased presence of capillaries next to remodeling sites in adult human cancellous bone. J Bone Miner Res. 2013; 28 (3): 574-85.
2. Bianco P, Sacchetti B, Riminucci M., Osteoprogenitors and the hematopoietic microenvironment. Best Pract Res Clin Haematol. 2011; 24 (1): 37-47.
3. Clines GA, Mohammad KS, Grunda JM, et al. Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor. J Bone Miner Res. 2011; 26 (10): 2523-36.
4. Chim SM, Tickner J, Chow ST, et al. Angiogenic factors in bone local environment. Cytokine Growth Factor Rev. 2013; 24 (3): 297-310.
5. Maes C, Goossens S, Bartunkova S, et al. Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones. EMBO J. 2010; 29 (2): 424-41.
6. Thompson B, Towler DA., Arterial calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol. 2012; 8 (9): 529-43.
7. Roche B, Vanden-Bossche A, Normand M, Malaval L, Vico L, Lafage-Proust M-H., Validated Laser Doppler protocol for measurement of mouse bone blood perfusion-response to age or ovariectomy differs with genetic background. Bone. 2013; 55 (2): 418-26.
8. Roche B, David V, Vanden-Bossche A, et al. Structure and quantification of microvascularisation within mouse long bones: What and how should we measure ? Bone. 2011; 50 (1): 390-9.
9. Schlüter KD, Piper HM., Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res. 1998; 37 (1): 34-41.
10. Prisby R, Menezes T, Campbell J., Vasodilation to PTH (1-84) in bone arteries is dependent upon the vascular endothelium and is mediated partially via VEGF signaling. Bone. 2013; 54 (1): 68-75.
11. Uzawa T, Hori M, Ejiri S, Ozawa H., Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone. Bone. 1995; 16 (4): 477-84.
12. Zhou H, Iida-Klein A, Lu SS, et al. Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone. 2003; 32 (5): 513-20.
13. Stresing V, Fournier PG, Bellahcene A, et al. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone. 2011; 48 (2): 259-66.
14. Bonnet N, Benhamou CL, Malaval L, et al. Low dose beta-blocker prevents ovariectomy-induced bone loss in rats without affecting heart functions. J Cell Physiol. 2008; 217 (3): 819-27.
15. Yang S, Nguyen ND, Center JR, Eisman JA, Nguyen TV., Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone. 2011; 48 (3): 451-5.
16. Song HJ, Lee J, Kim Y-J, et al. β1 selectivity of β-blockers and reduced risk of fractures in elderly hypertension patients. Bone. 2012; 51 (6): 1008-15.
17. Malaval L, Wade-Gueye NM, Boudiffa M, et al. Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J Exp Med. 2008; 205 (5): 1145-53.
18. Verhaar HJJ, Lems WF., PTH-analogs: comparable or different ? Arch Gerontol Geriatr. 2009; 49 (2): 130-2.
19. Clausen JO, Comment on Kanis, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2009; 20 (9): 1631.
20. Haddy FJ, Overbeck HW., Daugherty RM Jr., Peripheral vascular resistance. Annu Rev Med. 1968; 19: 167-1694.
21. Kapitola J, Zak J., [Effect of parathormone on bone blood flow in rats-possible role of NO]. Sb Lek. 2003; 104 (2): 133-7.
22. Brindley GW, Williams EA, Bronk JT, et al. Parathyroid hormone effects on skeletal exchangeable calcium and bone blood flow. Am J Physiol. 1988; 255 (1 Pt 2): H94-100.
23. Cochrane E, McCarthy ID., Rapid effects of parathyroid hormone(1-34) and prostaglandin E2 on bone blood flow and strontium clearance in the rat in vivo. J Endocrinol. 1991; 131 (3): 359-65.
24. Boelkins JN, Mazurkiewicz M, Mazur PE, Mueller WJ., Changes in blood flow to bones during the hypocalcemic and hypercalcemic phases of the response to parathyroid hormone. Endocrinology. 1976; 98 (2): 403-12.
25. Driessens M, Vanhoutte PM., Effect of calcitonin, hydrocortisone, and parathyroid hormone on canine bone blood vessels. Am J Physiol. 1981; 241 (1): H91-4.
26. Wang HH, Drugge ED, Yen YC, Blumenthal MR, Pang PK., Effects of synthetic parathyroid hormone on hemodynamics and regional blood flows. Eur J Pharmacol. 1984; 97 (3-4): 209-15.
27. Komrakova M, Krischek C, Wicke M, et al. Influence of intermittent administration of parathyroid hormone on muscle tissue and bone healing in orchiectomized rats or controls. J Endocrinol. 2011; 209 (1): 9-19.
28. Napoli C, William-Ignarro S, Byrns R, et al. Therapeutic targeting of the stem cell niche in experimental hindlimb ischemia. Nat Clin Pract Cardiovasc Med. 2008; 5 (9): 571-9.
29. Zaruba M-M, Huber BC, Brunner S, et al. Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival. Cardiovasc Res. 2008; 77 (4): 722-31.
30. Moore AEB, Blake GM, Taylor KA, et al. Assessment of regional changes in skeletal metabolism following 3 and 18 months of teriparatide treatment. J Bone Miner Res. 2010; 25 (5): 960-7.
31. Dobnig H, Turner RT., The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology. 1997; 138 (11): 4607-12.
32. Bouxsein ML, Pierroz DD, Glatt V, et al. beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice. J Bone Miner Res. 2005; 20 (4): 635-43.
33. Wang Y, Sakata T, Elalieh HZ, et al. Gender differences in the response of CD-1 mouse bone to parathyroid hormone: potential role of IGF-I. J Endocrinol. 2006; 189 (2): 279-87.
34. Weber K, Zeitz U, Bergow C, et al. Vitamin D-independent therapeutic effects of extracellular calcium in a mouse model of adult-onset secondary hyperparathyroidism. J Bone Miner Res. 2009; 24 (1): 22-32.
35. Locklin RM, Khosla S, Turner RT, Riggs BL., Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem. 2003; 89 (1): 180-90.
36. Jilka RL, O'Brien CA, Bartell SM, Weinstein RS, Manolagas SC., Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms. J Bone Miner Res. 2010; 25 (11): 2427-37.
37. Leblanc AJ, Krishnan L, Sullivan CJ, Williams SK, Hoying JB., Microvascular repair: post-angiogenesis vascular dynamics. Microcirculation. 2012; 19 (8): 676-95.
38. Prisby R, Guignandon A, Vanden-Bossche A, et al. Intermittent PTH 1-84 is osteoanabolic but not osteoangiogenic and relocates bone marrow blood vessels closer to bone forming sites. J Bone Min Res. 2011; 26 (11): 2583-96.
39. Dhillon RS, Xie C, Tyler W, et al. PTH enhanced structural allograft healing is associated with decreased angiopoietin-2 mediated arteriogenesis, mast cell accumulation and fibrosis. J Bone Miner Res. 2012; 28 (3): 586-97.
40. Brixen KT, Christensen PM, Ejersted C, Langdahl BL., Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. Basic Clin Pharmacol Toxicol. 2004; 94 (6): 260-70.
41. Díaz-Flores L, Gutiérrez R, Madrid JF, et al. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol Histopathol. 2009; 24 (7): 909-69.
42. Hasmim M, Bieler G, Rüegg C., Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost JTH. 2007; 5 (1): 166-73.
43. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002; 302 (3): 1055-61.
44. Tsai S-H, Huang P-H, Chang W-C, et al. Zoledronate inhibits ischemia-induced neovascularization by impairing the mobilization and function of endothelial progenitor cells. PloS One. 2012; 7 (7): e41065.
45. Yu YY, Lieu S, Hu D, Miclau T, Colnot C., Site specific effects of zoledronic acid during tibial and mandibular fracture repair. PLoS ONE. 2012; 7 (2): e31771.
46. Soki FN, Li X, Berry J, et al. The effects of zoledronic acid in the bone and vasculature support of hematopoietic stem cell niches. J Cell Biochem. 2013; 114 (1): 67-78.
47. Biver E, Vieillard MH, Cortet B, Salleron J, Falgayrac G, Penel G., No anti-angiogenic effect of clinical dosing regimens of a single zoledronic acid injection in an experimental bone healing site. Bone. 2010; 46 (3): 643-8.
48. Frost ML, Cook GJ, Blake GM, Marsden PK, Benatar NA, Fogelman I., A prospective study of risedronate on regional bone metabolism and blood flow at the lumbar spine measured by 18F-fluoride positron emission tomography. J Bone Min Res. 2003; 18 (12): 2215-22.
49. Kaczmarczyk-Sedlak I, Folwarczna J, Cegiela U, Nowinska B., Effect of pamidronate on the action of catecholamines on blood pressure in the marrow cavity of long bones in rats with prednisolone-induced osteoporosis. Pharmacol Rep. 2007; 59 (1): 58-63.
50. Pierroz DD, Bouxsein ML, Rizzoli R, Ferrari SL., Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice. Bone. 2006; 39 (2): 260-7.
51. Lamy S, Lachambre M-P, Lord-Dufour S, Béliveau R., Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol. 2010; 53 (5-6): 200-8.
52. Léauté-Labrèze C, de la Roque ED, Nacka F, et al. Double blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile hemangiomas in infants less than 4 months of age. Br J Dermatol. 2013; 169 (1): 181-3.
53. Hård A-L, Hellström A., On the use of antiangiogenetic medications for retinopathy of prematurity. Acta Paediatr Oslo Nor. 2011; 100 (8): 1063-5.
54. Lavine JA, Sang Y, Wang S, Ip MS, Sheibani N., Attenuation of choroidal neovascularization by β2-adrenoreceptor antagonism. JAMA Ophthalmol. 2013; 131 (3): 376-82.
55. Brinker MR, Lippton HL, Cook SD, Hyman AL., Pharmacological regulation of the circulation of bone. J Bone Joint Surg Am. 1990; 72 (7): 964-75.
56. Dean MT, Wood MB, Vanhoutte PM., Antagonist drugs and bone vascular smooth muscle. J Orthop Res. 1992; 10 (1): 104-11.
57. Tran MA., The effect of lumbar sympathetic stimulation on the vasculature of bone. Br J Pharmacol. 1980; 70 (3): 363-6.
58. Boerckel JD, Uhrig BA, Willett NJ, Huebsch N, Guldberg RE., Mechanical regulation of vascular growth and tissue regeneration in vivo. Proc Natl Acad Sci USA. 2011; 108 (37): 674-80.
59. Maes C., Role and regulation of vascularization processes in endochondral bones. Calcif Tissue Int. 2013; 92 (4): 307-23.
60. Yao Z, Lafage-Proust M-H, Plouët J, Bloomfield S, Alexandre C, Vico L., Increase of both angiogenesis and bone mass in response to exercise depends on VEGF. J Bone Miner Res. 2004; 19 (9): 1471-80.
61. Brookes M, Revell WJ., Blood supply of bone. Berlin: Springer Verlag; 1998.